Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Other Non-Current Liabilities: 2013-2025

Historic Other Non-Current Liabilities for Ocular Therapeutix (OCUL) over the last 7 years, with Sep 2025 value amounting to $15.0 million.

  • Ocular Therapeutix's Other Non-Current Liabilities rose 3.44% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 3.44%. This contributed to the annual value of $13.2 million for FY2024, which is 55.83% down from last year.
  • As of Q3 2025, Ocular Therapeutix's Other Non-Current Liabilities stood at $15.0 million, which was up 6.69% from $14.0 million recorded in Q2 2025.
  • Over the past 5 years, Ocular Therapeutix's Other Non-Current Liabilities peaked at $73.3 million during Q1 2021, and registered a low of $6.4 million during Q4 2022.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $14.5 million (2024), whereas its average is $17.4 million.
  • Per our database at Business Quant, Ocular Therapeutix's Other Non-Current Liabilities plummeted by 82.54% in 2022 and then skyrocketed by 372.16% in 2023.
  • Ocular Therapeutix's Other Non-Current Liabilities (Quarterly) stood at $20.2 million in 2021, then tumbled by 68.55% to $6.4 million in 2022, then surged by 372.16% to $30.0 million in 2023, then crashed by 55.83% to $13.2 million in 2024, then increased by 3.44% to $15.0 million in 2025.
  • Its last three reported values are $15.0 million in Q3 2025, $14.0 million for Q2 2025, and $13.9 million during Q1 2025.